June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Ocular side effects of novel and traditional chemotherapeutic agents
Author Affiliations & Notes
  • Anne Kunkler
    The Ohio State University, Columbus, Ohio, United States
  • Kari Kendra
    The Ohio State University, Columbus, Ohio, United States
  • Colleen M Cebulla
    The Ohio State University, Columbus, Ohio, United States
  • Footnotes
    Commercial Relationships   Anne Kunkler, None; Kari Kendra, None; Colleen Cebulla, None
  • Footnotes
    Support  Ohio Lions Eye Research Foundation; K08EY022672 from the National Eye Institute of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding institutions. Clinical trial support from Bristol-Myers Squibb.
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5166. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Anne Kunkler, Kari Kendra, Colleen M Cebulla; Ocular side effects of novel and traditional chemotherapeutic agents. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5166.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Traditional and novel chemotherapeutics improve the prognosis and quality of life for a variety of malignancies. However, limited data are available regarding the ocular side effects of many of these novel agents. This retrospective, observational study aims to examine the ocular side effects of chemotherapeutic agents in patients treated for their malignancy at The Ohio State University.

Methods : Approval was obtained from the institutional review board at the Ohio State University. An ICD-9 search of the electronic medical record was performed for patients treated with high risk medications who were seen in the department of ophthalmology between 1/1/2010 and 2/2/2015. This search yielded 3,531 cases. The first 2,000 charts were reported previously (ARVO 2016). The last 1,531 charts were analyzed herein. A temporal association between chemotherapeutic use and development of the side effect was deemed necessary for inclusion.

Results : Eight of the 1500 patients analyzed were oncologic patients who developed ocular side effects. The patients were being treated with Veliparib, ARRY-438162, Pimasertib/SAR245409, Ibrutinib, Ipilimumab, Paclitaxel, and Pemetrexed. The most common presenting symptoms were anterior segment side effects (red eye, dry eye, epiphora, and/or eyelid edema (4/8 or 50%)). The most common medication with anterior side effects was Ibrutinib (2/8 patients), which also induced photophobia and headache. Posterior ocular side effects were noted in a patient treated with a MEK inhibitor (ARRY-438162) who developed subretinal fluid and a patient treated with Ipilimumab developed bilateral macular edema. Pemetrexed, an antimetabolite, was associated with development of a visual field defect and suspected ischemic optic neuropathy. Every patient remained on treatment; 4 patients had resolution without changing the drug, 1 experienced complete resolution after decreasing the dose, and 3 continued to have ocular effects while on drug.

Conclusions : The ocular side effects found in this review were generally mild to moderate, with most either resolving while remaining on treatment or at a reduced dose.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×